PectaSol-C® Modified Citrus Pectin, 270 V-caps

$74.00 (as of March 31, 2018, 8:40 am) $69.88

Usually ships in 24 hours


Item Catalog Number: 01080 PectaSol-C® Modified Citrus Pectin (MCP) is a natural product that is derived from the peel pith of citrus fruit. It is formulated to: Support healthy cellular growth* Promote normal tissue health* Support healthy immune function* Pectin Chemistry Pectin is a soluble dietary fiber composed of galacturonic acid and varying amounts of galactose, glucose, rhammose, and arabinose. In its natural state, the galacturonic groups are found esterified. Regular pectin is not absorbed due to its large size, but it nevertheless plays a key dietary role in supporting digestive and cardiovascular health. It is also commonly used as a gelling agent in foods. PectaSol-C® MCP PectaSol-C MCP is a special class of pectin that was developed by Isaac Eliaz, MD, LAc. Dr. Eliaz has researched and published articles on citrus pectin for over a decade. MCP is protected by US patents #6,274,566, #6,462,029, and #7,026,302. PectaSol-C MCP is produced using a scientifically validated proprietary process that carefully controls both the molecular weight (MW) and degree of esterification (DE). The specific low molecular weight size range of PectaSol-C® MCP allows easy absorption into the bloodstream with the effective range of molecular size and esterification.* Pre-Production Research on PectaSol® MCP Dr. Eliaz developed the PectalSol® brand as the first modified citrus pectin for human use. This MCP is designed to be a superior ligand for galectin-3 and involved extensive preproduction research. A cell culture model using aberrant prostate cells was used to help determine the optimal MW and DE by demonstrating cytotoxicity (cell death).* After optimization, PectaSol® was immediately tested clinically. Clinical Trials PectaSol® is the only brand of modified citrus pectin that has been validated in human clinical trials. PectaSol-C® MCP is an integral part of Dr. Eliaz’ Healthy Cellular Support Protocols. Recent Developments Th